[go: up one dir, main page]

LV10051A - How to get lyophilisate ifosfamida - Google Patents

How to get lyophilisate ifosfamida

Info

Publication number
LV10051A
LV10051A LV920174A LV920174A LV10051A LV 10051 A LV10051 A LV 10051A LV 920174 A LV920174 A LV 920174A LV 920174 A LV920174 A LV 920174A LV 10051 A LV10051 A LV 10051A
Authority
LV
Latvia
Prior art keywords
ifosfamida
lyophilisate
ifosfamide
weight
hexitol
Prior art date
Application number
LV920174A
Other languages
Latvian (lv)
Other versions
LV10051B (en
Inventor
Uwe-Peter Damann
Otto Isaac
Dieter Sauerbier
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of LV10051A publication Critical patent/LV10051A/en
Publication of LV10051B publication Critical patent/LV10051B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Control Of El Displays (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Amplifiers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

1. A lyophilized preparation consisting of ifosfamide and 0.1 to 17 parts by weight hexitol per part by weight ifosfamide and, optionally, other standard pharmaceutical auxiliaries.
LVP-92-174A 1986-10-31 1992-10-27 Method for producing of lyophilized yphosphamide LV10051B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3637089 1986-10-31

Publications (2)

Publication Number Publication Date
LV10051A true LV10051A (en) 1994-05-10
LV10051B LV10051B (en) 1995-06-20

Family

ID=6312873

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-92-174A LV10051B (en) 1986-10-31 1992-10-27 Method for producing of lyophilized yphosphamide

Country Status (25)

Country Link
EP (1) EP0265812B1 (en)
JP (1) JPS63159319A (en)
KR (1) KR900003491B1 (en)
AT (1) ATE55250T1 (en)
AU (1) AU598602B2 (en)
CA (1) CA1314231C (en)
DD (1) DD262582A5 (en)
DE (1) DE3764235D1 (en)
DK (1) DK169308B1 (en)
EG (1) EG18333A (en)
ES (1) ES2017982B3 (en)
FI (1) FI87140C (en)
GE (1) GEP19971025B (en)
GR (1) GR3000708T3 (en)
HU (1) HU197987B (en)
IL (1) IL84312A (en)
IN (1) IN168119B (en)
LV (1) LV10051B (en)
MX (1) MX8958A (en)
NO (1) NO873860L (en)
PT (1) PT86032B (en)
RU (1) RU1836079C (en)
UA (1) UA11075A (en)
YU (1) YU197387A (en)
ZA (1) ZA878183B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2040394T3 (en) * 1988-03-19 1993-10-16 Asta Medica Aktiengesellschaft PROCEDURE FOR PREPARING A LYOPHILIZED MATERIAL OF IFOSFAMIDE AND MESNA.
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
DE19529057B4 (en) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamide lyophilizate preparations
EA003864B1 (en) * 1998-03-03 2003-10-30 ШИОНОГИ энд КО.,ЛТД. COMPOSITION AND METHOD OF PREPARING OF PHARMACEUTICAL FORMULATION, LYOPHILIZED COMPOSITION AND USE OF IT, METHOD OF INHIBITING sPLA2-MEDIATED RELEASE OF FATTY ACID, METHOD OF TREATING A MAMMALS, METHOD OF TREATMENT OR PREVENTING SEPSIS, SEALED CONTAINER
US20050272698A1 (en) * 2002-09-05 2005-12-08 Daftary Gautam V Liquid stable composition of oxazaphosphorine with mesna
WO2004050012A2 (en) * 2002-12-02 2004-06-17 Bharat Serums And Vaccines Ltd Ifosfamide compositions for parenteral administration and a process for their preparation
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
BRPI0715279A2 (en) * 2006-09-29 2013-06-11 Infa Sa packaging system, packaging system for a pharmaceutical composition, method for transferring a pharmaceutical composition for intravenous infusion administration, use of a packaging system, intravenous access parenteral drug delivery kit and parenteral administration kit of active principles
WO2016087001A1 (en) * 2014-12-04 2016-06-09 Huawei Technologies Co., Ltd. Load allocation in a data communication network

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
DE2750207A1 (en) * 1977-05-09 1978-11-16 Walton J Smith Anhydrous compsn. prodn. by freeze drying hydrated, hydrolysable prod. - esp. aspirin or aspirin salt solns.
EP0083439B1 (en) * 1981-12-31 1989-07-26 ASTA Pharma AG 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide

Also Published As

Publication number Publication date
KR880004814A (en) 1988-06-27
LV10051B (en) 1995-06-20
DE3764235D1 (en) 1990-09-13
PT86032A (en) 1987-11-01
NO873860L (en) 1988-05-02
FI874727A (en) 1988-05-01
RU1836079C (en) 1993-08-23
NO873860D0 (en) 1987-09-15
JPH0543684B2 (en) 1993-07-02
FI874727A0 (en) 1987-10-27
DK569687A (en) 1988-05-01
GR3000708T3 (en) 1991-10-10
CA1314231C (en) 1993-03-09
FI87140B (en) 1992-08-31
DK169308B1 (en) 1994-10-10
AU8052987A (en) 1988-05-05
ATE55250T1 (en) 1990-08-15
DK569687D0 (en) 1987-10-30
EP0265812A1 (en) 1988-05-04
MX8958A (en) 1993-12-01
IN168119B (en) 1991-02-09
GEP19971025B (en) 1997-04-06
ES2017982B3 (en) 1991-03-16
FI87140C (en) 1992-12-10
HUT44932A (en) 1988-05-30
IL84312A (en) 1991-11-21
YU197387A (en) 1988-12-31
ZA878183B (en) 1988-05-02
PT86032B (en) 1990-08-31
KR900003491B1 (en) 1990-05-21
HU197987B (en) 1989-07-28
EP0265812B1 (en) 1990-08-08
EG18333A (en) 1993-12-30
DD262582A5 (en) 1988-12-07
IL84312A0 (en) 1988-03-31
UA11075A (en) 1996-12-25
AU598602B2 (en) 1990-06-28
JPS63159319A (en) 1988-07-02

Similar Documents

Publication Publication Date Title
FI891283A (en) IFOSFAMID-MESNA-LYOFILISAT AND FOERFARANDE FOER DESS FRAMSTAELLNING.
DE3855451D1 (en) Substituted 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
DK275488A (en) indolone derivatives
ATE66143T1 (en) SLOW RELEASE SOLID PREPARATION.
GR890100838A (en) A novel therapeutic active compound and preparation method therefore.
SE8603582D0 (en) COMPOSITION CONTAINING L-DOPA
LV10051A (en) How to get lyophilisate ifosfamida
IT1212143B (en) COMPOSITION WITH TRICHOGENIC ACTIVITY.
BG60101B2 (en) Method for preparing of 4-fluoro-2-[[(4-methoxy-2-pyridinyl)methyl]thionil]-1h-benzimidazo le
DK103987D0 (en) SUBSTITUTED 1,3,4,9-TETRAHYDROPYRANOE3,4-BAAINDOL-L-ACETIC ACIDS, THEIR PREPARATION AND USE AS MEDICINAL PRODUCTS
IL84551A (en) Peptides,their preparation and pharmaceutical compositions containing them
FR2603284B1 (en) 7-OXABICYCLO ACID DERIVATIVES (2.2.1.) HYDROXAMIC HEPTANE WITH THERAPEUTIC ACTION
NO167801C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 2,2'-BI-1H IMIDAZOLD DERIVATIVES.
OA09419A (en) 3-Pyrrolidinylthio-1-azabicyclo (3.2.0.) -Hept-2-ene-2-carboxylic acid derivatives and their preparation.
ATE67674T1 (en) PHARMACEUTICAL PREPARATIONS WITH HEALING ACTIVITY.
IT213056Z2 (en) TIPS TO ASSEMBLE THE OPENERS ON AGRICULTURAL TRACTORS WITHOUT AFFECTING THE NECESSARY MECHANICAL STRENGTH OF THE SET